Journal of Bioequivalence & Bioavailability

The evolving landscape of biobetters: Advantages & challenges of being better

Joint Event on 4^th International Conference on Drug Discovery, Designing Chemistry and Pharmaceutical Analysis & International Conference on Biobetters and Regulatory Affairs

June 27-28, 2018 | Vancouver, Canada

Kooros Motamed-Larijani

NantBioscience Inc., USA

Keynote: J Bioequiv Availab

Abstract:

???Biobetters??? or ???Biosuperiors??? are enhanced versions of approved biological products. Whereas ???Biosimilars??? are near-perfect copies of the originators, biobetters differentiate themselves through displaying superiority over the reference biologics. These improvements in one or more attributes could be in the form of increased efficacy and/or safety, reduced immunogenicity, changes in route of delivery, reduced dosing frequency/cost of treatment or improvements in manufacturing. In spite of these potential advantages over the branded biologic or an approved biosimilar, biobetters also face various clinical development, regulatory and marketing hurdles which will be addressed. In summary, biobetters represent an opportunity to establish brand-to-brand competition within treatment indications and can be perceived as a potential path to provide meaningful improvements over the original biologic, sustain innovation and market differentiation in order to drive future value.

Biography :

Kooros Motamed-Larijani has been the Director of Drug Development at Nant-Bioscience Inc. since April 2016. Previously, he served as VP of Strategic Alliances and Clinical Communications and VP of Clinical Development and Nanomedicine at Sorrento Therapeutics Inc. from 2013 to 2016. He also served as a co-founder and CSO/CTO of Igdrasol Inc. and Biomiga Diagnostics LLC start-up companies from 2011-2013. Prior to that, Dr. Motamed served as the MOA and Molecular Biology Group Head at Celgene Corp. and Abraxis Bioscience LLC. from 2007-2011. Dr. Motamed held an Assistant Professorship position in the Department of Pathology and Vascular Biology Center at Medical College of Georgia, Augusta from 2002-2007. He has over 30 original publications in peer-reviewed journals, over 50 conference presentations and 5 issued patents. He has served on the Editorial Board of Journal of Nanomaterials & Molecular Nanotechnology since 2013. Dr. Motamed received a B.S. degree in Biology from University of San Francisco and a Ph.D. degree from the University of California, Davis in Microbiology.

E-mail: kouros.motamed@nantbio.com